96-well light gray 1/2 area microplate. Half-area plates utilize the same well spacing as a regular 96-well plate, but contain wells with half the diameter of a typical 96-well plate. This enables miniaturization to lower assay volumes while retaining ease-of-pipetting. Light gray plates can help minimize cross-talk while maintaining high signal in luminescent and Alpha assays.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
PerkinElmer's ½ AreaPlate offers same well depth at half the size to help you miniaturize your assay, designed to utilize cost reduction advantages without going to a 384-well format.
PerkinElmer is proud to have designed a light gray microplate which addresses unique challenges of sample screening. Our uniquely engineered 384 well and 1536 well light gray AlphaPlate microplates combine the best features of white microplates (excellent signal-to-background) and black microplates (decreased well-to-well crosstalk) for superior assay window and sensitivity in comparison to any other plate for luminescence assays. Our AlphaPlates are designed for a variety of technologies for luminescence based assays, but are specifically designed for use with PerkinElmer’s AlphaLISA and AlphaScreen technologies.
It’s important to choose the correct microplate prior to your screening project. By choosing the incorrect microplate, challenges such as missed data points, sample re-screening, missed project timelines and ultimately higher costs can be incurred.
|Detection Method||Luminescence, Alpha|
|Product Brand Name||½ AreaPlate|
|Unit Size||2 x 25 plates|
Technical advancements in antibody engineering has brought about greater interest in more novel antibody therapeutic design and the emergence of new classes of antibody therapeutics called bispecific antibodies (bsAbs). The principle behind bispecific antibody design is to create an antibody / an ...
When Non-alcoholic fatty liver disease (NAFLD) progresses to nonalcoholic steatohepatitis (NASH), with inflammation and damage to liver cells it can cause fibrosis, cirrhosis and liver failure or cancer. Despite the prevalence of NAFLD and NASH rising, their remains no approved treatments. But st ...